ProQR Reports Q1 2026 Results, Advances RNA Editing Pipeline, and Refines Lead Program Strategy

summarizeSummary

ProQR Therapeutics announced its Q1 2026 financial results, reporting an increased net loss but reduced cash burn, while also providing key updates on its RNA editing pipeline, including a strategic shift for its lead program AX-0810.

check_boxKey Events

• Q1 2026 Financial Results

  ProQR reported a net loss of €13.4 million (€0.13 per diluted share) for Q1 2026, compared to a net loss of €10.1 million (€0.10 per diluted share) for Q1 2025. Net cash used in operating activities decreased to €11.1 million from €15.8 million year-over-year, with cash and cash equivalents of €81.1 million at quarter-end, supporting a runway into mid-2027.

• AX-0810 Program Update

  The lead RNA editing program, AX-0810, remains on track to report target engagement data from healthy volunteers in Q2 2026. The company has selected biliary atresia as the initial Phase 2 indication, planning an investigator-initiated trial in pediatric participants in China, with initial clinical data targeted for H1 2027.

• Pipeline Expansion and Upcoming Catalysts

  ProQR is advancing multiple programs toward the clinic, including AX-0811 (NTCP) with a CTA filing expected mid-2026 and initial data by year-end 2026, AX-0422 (IDUA) with a CTA filing early 2027 and initial data in H1 2027, and AX-2911 (PNPLA3) anticipating a first-in-human IIT in China in H1 2027.

• Axiomer Platform Advancement

  The company continues to enhance its Axiomer platform through AI-enabled discovery, reiterating its strategic partnership with Ginkgo Bioworks (announced April 8, 2026) and the formation of an AI Advisory Board to accelerate RNA editing therapeutic development.

auto_awesomeAnalysis

ProQR Therapeutics reported an increased net loss for Q1 2026, but demonstrated improved operational efficiency with reduced cash used in operations compared to the prior year, maintaining its cash runway into mid-2027. The company provided significant updates on its RNA editing pipeline, including a strategic shift for its lead program AX-0810 to prioritize biliary atresia for Phase 2 development via an investigator-initiated trial in China, with initial data targeted for H1 2027. This indicates active R&D and a focused approach to clinical development.